Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lamivudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | POLG | P54098 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamivudine SCHEMBL3444480 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL109675 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL33979 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12964486 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2305925 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2240686 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12996723 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL465678 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2806818 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL13006083 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105434454-A | HBV drug-resistant strain infection treating drug composition | UNIV FUDAN | 2016-03-30 | — | — | CN | claimed |
| CN-103585178-A | Application of human stem cell composition in preparing medicine for treating AIDS | TANG MINGQI | 2014-02-19 | — | — | CN | claimed |
| CN-101130063-B | Colon targeting preparation of liver protein polypeptide and preparation method thereof | LI LI | 2010-12-29 | — | — | CN | claimed |
| CN-116836189-A | Fluoroalkyl and aza group substituted boron-containing nucleoside analogue precursor, synthesis method thereof and matched use of BNCT therapy | 吴卫东 | 2023-10-03 | — | — | CN | disclosed |
| US-20230270677-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2023-08-31 | — | — | US | disclosed |
| CN-116322788-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116178292-A | Fluoroalkyl and aza group substituted nucleoside analogue precursor, its synthesis method and medical use | 吴卫东 | 2023-05-30 | — | — | CN | disclosed |
| CN-115397987-A | Method of modulating human L1 retrotransposon RNA and compositions for use therein | 阿卜杜拉国王科技大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-114901363-A | Long-acting therapeutic compositions and methods thereof | 华盛顿大学 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021142150-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | UNIVERSITY OF WASHINGTON (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021076977-A1 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2021-04-22 | — | — | WO | disclosed |
| EP-1551419-A2 | RELIEF OF AIDS SYMPTOMS | Bio-Defense Nutritionals (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1592684-A | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | BURSTEIN TECHNOLOGIES INC (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1480772-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | Burstein Technologies, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003101389-A2 | RELIEF OF AIDS SYMPTOMS | BIO-DEFENSE NUTRITIONALS (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030129665-A1 | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | VINDUR TECHNOLOGIES, INC. (NO) | 2003-07-10 | — | — | US | disclosed |
| US-20030092145-A1 | Viral vaccine composition, process, and methods of use | IMMUNITOR USA INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003021223-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | BURSTEIN TECHNOLOGIES, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | ALB 4843/4885LMNA 3550/4885PDE3A 736/4885 |
| US-20230270677-A1 | LONG-ACTING THERAPEUTIC AGENT COMBINATIONS AND METHODS THEREOF | VEGFA, ADAR, EIF2AK2 | ALB 1072/4885LMNA 2579/4885PDE3A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.